Prix Galien Italia 2021: IBSA presents an innovative formulation in the osteoarticular area30 June 2021
IBSA is proud to announce its presence at the Prix Galien 2021 edition, with an innovative formulation that combines hyaluronic acid and biotechnological chondroitin in the osteo-articular field.
The Prix Galien, established in France in 1970, has been present in Italy since 1992 and is the most prestigious international competition at the pharmaceutical level. The award aims to promote and reward the most significant and innovative advances and products in the healthcare sector. Over the years it has acquired more and more relevance among institutions and professionals.
IBSA, one of the world leaders in the production of hyaluronic acid that manages the entire product supply chain, from production to finished product, is about to launch a new formulation of hyaluronic acid and chondroitin, both made via bio-fermentation through IBSA patented processes rather than animal extraction.
It is a medical device developed thanks to the collaboration between our Research and Development department and some relevant Italian research centers such as Vanvitelli University (Naples), Campus Biomedico (Rome) and San Raffaele (Milan). As explained by Andrea Giori, R&D Director of IBSA Farmaceutici, "We were able to associate sodium chondroitin with hyaluronic acid using NAHYCO® TECHNOLOGY, a patented thermal process that allows for the formation of weak bonds between the two components of different molecular weight, leading to complex molecular hybrids. This production process allows to obtain a highly concentrated hyaluronic acid gel, optimizing its visco-elastic properties".
The new medical device, which will soon expand IBSA therapeutic porfolio in the osteo-articular area, represents an example of “Made in Italy” excellence and innovation that has now the opportunity to be celebrated and promoted throughout the prestigious Prix Galien 2021 competition.